BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29424351)

  • 1. Ca2+-dependent calcineurin/NFAT signaling in β-adrenergic-induced cardiac hypertrophy.
    Khalilimeybodi A; Daneshmehr A; Sharif Kashani B
    Gen Physiol Biophys; 2018 Jan; 37(1):41-56. PubMed ID: 29424351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.
    Tsai CY; Kuo WW; Shibu MA; Lin YM; Liu CN; Chen YH; Day CH; Shen CY; Viswanadha VP; Huang CY
    PLoS One; 2017; 12(9):e0184153. PubMed ID: 28863192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating β-adrenergic-induced cardiac hypertrophy through computational approach: classical and non-classical pathways.
    Khalilimeybodi A; Daneshmehr A; Sharif-Kashani B
    J Physiol Sci; 2018 Jul; 68(4):503-520. PubMed ID: 28674776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRPC4α and TRPC4β Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation.
    Kirschmer N; Bandleon S; von Ehrlich-Treuenstätt V; Hartmann S; Schaaf A; Lamprecht AK; Miranda-Laferte E; Langsenlehner T; Ritter O; Eder P
    PLoS One; 2016; 11(12):e0168446. PubMed ID: 27992507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptin-induced cardiomyocyte hypertrophy reveals both calcium-dependent and calcium-independent/RhoA-dependent calcineurin activation and NFAT nuclear translocation.
    Rajapurohitam V; Izaddoustdar F; Martinez-Abundis E; Karmazyn M
    Cell Signal; 2012 Dec; 24(12):2283-90. PubMed ID: 22917533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes.
    MacDonnell SM; Weisser-Thomas J; Kubo H; Hanscome M; Liu Q; Jaleel N; Berretta R; Chen X; Brown JH; Sabri AK; Molkentin JD; Houser SR
    Circ Res; 2009 Aug; 105(4):316-25. PubMed ID: 19608982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of NFAT cycling to cytosolic calcium concentration: implications for hypertrophic signals in cardiac myocytes.
    Cooling MT; Hunter P; Crampin EJ
    Biophys J; 2009 Mar; 96(6):2095-104. PubMed ID: 19289036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling.
    Pare GC; Bauman AL; McHenry M; Michel JJ; Dodge-Kafka KL; Kapiloff MS
    J Cell Sci; 2005 Dec; 118(Pt 23):5637-46. PubMed ID: 16306226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
    Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
    Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
    Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
    Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
    Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
    Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway.
    Lu M; Wang H; Wang J; Zhang J; Yang J; Liang L; Maslov LN
    Planta Med; 2014 Jan; 80(1):63-9. PubMed ID: 24338553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes?
    Houser SR; Molkentin JD
    Sci Signal; 2008 Jun; 1(25):pe31. PubMed ID: 18577756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
    Zhou X; Zhang Q; Zhao T; Bai X; Yuan W; Wu Y; Liu D; Li S; Ju J; Chege Gitau S; Chu W; Xu C; Lu Y
    Eur J Pharmacol; 2014 Jul; 735():202-10. PubMed ID: 24769415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling.
    Gao H; Wang F; Wang W; Makarewich CA; Zhang H; Kubo H; Berretta RM; Barr LA; Molkentin JD; Houser SR
    J Mol Cell Cardiol; 2012 Nov; 53(5):657-67. PubMed ID: 22921230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.